<DOC>
	<DOCNO>NCT00144300</DOCNO>
	<brief_summary>To determine difference presence retinal deterioration PD patient treat pramipexole IR versus ropinirole monitor comprehensive ophthalmologic assessment baseline end study two year .</brief_summary>
	<brief_title>Ophthalmologic Safety Study Pramipexole Immediate Release ( IR ) Versus Ropinirole Early Parkinson 's Disease ( PD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion Diagnosis main criterion inclusion . Patients must meet follow inclusion criterion eligible enrollment study : 1 . Patients idiopathic Parkinson 's disease le 7 year characterize Stage IIII Modified Hoehn Yahr Scale maximum 6 month cumulative lifetime exposure levodopa and/or dopamine agonist . Patients current dopamine agonist therapy would require 14day washout . 2 . Age least 30 year . 3 . Women childbearing potential must negative serum betaHCG pregnancy test Screen ( Baseline ) visit patient must use adequate contraceptive method . 4 . Evidence personally sign date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect study . 5 . Patients willing able comply schedule visit , treatment plan , study procedure . Exclusion criterion Main criterion exclusion . The presence follow would make patient ineligible enrollment study : 1 . Previous history allergic response complication dopaminergic agonist drug 2 . Atypical PD syndromes 3 . History stereotactic brain surgery 4 . Positive hepatitis B ( surface antigen ) hepatitis C ( antibody ) 5 . Surgery within 180 day randomization would negatively impact participation 6 . Folstein 's Mini Mental State Examination ( MMSE ) score 24 less 7 . History active epilepsy ( seizure ) past 1 year 8 . Third degree AV block sick sinus syndrome 9 . Congestive heart failure , Class III IV 10 . Unstable heart disease unstable angina , dysrhythmia , myocardial infarction prior 6 month 11 . Symptomatic orthostatic hypotension 12 . Clinically significant liver disease renal disease 13 . Malignant melanoma history previously treat malignant melanoma . 14 . Prohibited medication take ( include drug know potential retinotoxic effect take prior 12 month ; neuroleptic take within prior 6 month , MAO inhibitor except rasagiline selegiline take within prior 3 month , betablockers take treat Parkinson 's disease prior 30 day , Coenzyme Q10 take within 14 day ) 15 . Albinism/Albinoidism degree , type syndrome 16 . History glaucoma without treatment 17 . Inherited acquire retinopathy agerelated macular degeneration visual loss 18 . Sarcoidosis 19 . Diabetes mellitus degree even diet insulin control 20 . Best correct visual acuity ( BCVA ) less 20/40 ETDRS 21 . Refractive error great minus6 diopter 22 . Abnormal electroretinogram ( ERG ) 23 . Unable dilate pupil 24 . History severe eye trauma might affect outcome study 25 . History psychosis 26 . Participation investigational drug study use investigational drug within prior 30 day</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>